Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
November 4th, 2022
Cogstate Signs US$17.9 Million of Contracts in September Quarter
Read More
October 18th, 2022
Dimerix – Recruitment Accelerating in Phase III Study
Read More
October 18th, 2022
Antisense Therapeutics Revises Clinical Program in DMD
Read More
October 5th, 2022
Pharmaxis - Encouraging Early Data from Scar Removal Study
Read More
October 5th, 2022
Anteris Technologies - Aortic Valve Outperforms Surgical and TAVR Competitors
Read More
October 5th, 2022
Eisai Delivers Positive Phase III Alzheimer's Data
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
September 19th, 2022
ResApp Health Sold to Pfizer for $180 Million
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
September 19th, 2022
Imugene to Raise $80 Million
Read More
September 19th, 2022
Cogstate - Investors Await Lecanemab Phase III Data
Read More
September 9th, 2022
Pharmaxis Repurposes PXS-4728 for Parkinson's Disease
Read More
September 9th, 2022
Patrys Passes Final Manufacturing Tests for PAT-DX1
Read More
September 9th, 2022
Anteris Technologies to Present Key Data at TCT this Month
Read More
September 9th, 2022
Patrys Passes Final Manufacturing Tests for PAT-DX1
Read More
August 19th, 2022
Opthea – Novel Funding to Access US$260 Million
Read More
August 19th, 2022
Anteris Technologies to Move to Pivotal Study as Positive Results Continue
Read More
August 5th, 2022
Pharmaxis Sells Orbital Technology for US$5 Million
Read More
August 5th, 2022
Neuren Pharmaceuticals - Partner Files Trofinetide for US Approval
Read More
August 5th, 2022
Imricor - Europe the Key Focus
Read More
Pages
1
2
3
4
5
6
7
8
9
